Fake Endorsements : The website falsely claims the product is recommended by organizations like the Australian Obesity Society and Diabetes Australia neither has verified affiliation
HCPs must be aware that comprehensive dietary education, flexibility during the dose-escalation phase and appropriate symptomatic treatment of persistent GI AEs are factors of paramount importance to minimize the GI side effects associated with GLP-1 RA use
Dallas provides a valuable testing ground to refine our AI against diverse weather and complex road networks
Viking Therapeutics Sector: Dual and triple agonists for obesity, metabolic, and liver disease HQ: San Diego, CA Year Founded: 2012 Origin Story: The company built its pipeline around small molecule and peptide candidates licensed from academic and pharma sources, eventually advancing VK2735, a dual GLP-1/GIP receptor agonist designed to be the first such therapy available in both oral and injectable formulations
The risk of yo-yo effects, where patients lose muscle on the drug and regain fat after stopping, is a real concern
